Rates of major bleeding and intracranial hemorrhage are similar for apixaban and dabigatran versus aspirin, while rates are ...

Experts discuss PPI use for GI protection in patients on antithrombotics, highlighting risk factors, dosing, drug ...

A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...

Background Differences in the clinical outcomes and level of risk among Asian versus non-Asian patients with atrial ...

Aplagon announces EUR 7 million financing to advance its APAC therapeutic for thrombo-inflammatory diseases into phase 2A trials: Helsinki Tuesday, February 4, 2025, 16:00 Hrs [IS ...

A scientific statement has been published by the AHA regarding obstetric and cardiovascular risk in patients receiving assisted reproductive technology.

Oral anticoagulant or antiplatelet medication use had no substantial effect on the accuracy of multitarget stool DNA testing for colorectal cancer, according to a study published in Gastro Hep ...

Financing led by new Investors Fåhraeus Startup and Growth and EIC FundHELSINKI, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Aplagon, a ...

Kyprolis can interact with anticoagulants and antiplatelets, which are prescribed to treat and help prevent blood clots. Kyprolis, as well as antiplatelets and anticoagulants, increases your risk ...

Long-term oral anticoagulants (OACs) and dual-antiplatelet therapy represent the recommended treatment in patients with atrial fibrillation and a high CHA 2 DS 2-VASc score, and in patients ...

For example, in patients receiving oral anticoagulation (OAC), the guidelines prioritize bleeding prevention to guide decisions on dual antiplatelet therapy (DAPT) initiation and duration, the authors ...